AI Analysis
AI-generated analysis. Always verify with the original filing.
Lantern Pharma reported a GAAP net loss of -$17.1M and operating income of -$18.0M for FY 2025, reflecting ongoing clinical development costs amid reduced holdings of marketable securities. Free cash flow was -$15.7M, underscoring the need for substantial additional funding to advance trials.
Key Takeaways
1Net income was -$17.1M, as management noted continued losses from research and development activities in oncology drug candidates.
2Operating income was -$18.0M, driven by clinical trial expenses that may require future adjustments if cost estimates for trials or services change.
3Diluted EPS was $-1.57, consistent with net losses incurred while advancing precision ADC development platforms for cancer.
4Net cash provided by operating activities was -$15.7M, partially offset by a smaller increase in accounts payable and accrued expenses compared to the prior year.
5Free cash flow was -$15.7M, calculated as operating cash flow less minimal capital expenditures of $1,715, highlighting cash preservation efforts.
6Cash flow uses decreased primarily due to reductions in marketable securities held during FY 2025 versus FY 2024.